The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study
Abstract
Purpose: To compare fotemustine and dacarbazine (DTIC) in terms of overall response rate (ORR) as primary end-point and overall survival, duration of responses, time to progression, time to occurrence of brain metastases (BM), and to assess safety and quality of life in patients with disseminated cutaneous melanoma. Patients and Methods: Patients received either intravenous fotemustine 100 mg/m 2 weekly for 3 weeks or DTIC 250 mg/m 2/d for 5 consecutive days every 4 weeks (two cycles). Nonprogressive patients received a maintenance treatment every 4 weeks (fotemustine 100 mg/m 2 or DTIC 250 mg/m 2 for 5 days). Results: Two hundred twenty-nine patients were randomly assigned to fotemustine or DTIC arms. The best ORR was higher in the fotemustine arm than in the DTIC arm in the intent-to-treat population (n = 229; 15.2% v 6.8%; P = .043) and in full analysis set (n = 221) (15.5% v 7.2%; P = .053). Similar median durations of responses (5.8 months with fotemustine v 6.9 months with DTIC) and time to progression (1.8 v 1.9 months, respectively) were observed. In patients without BM at inclusion, the median time to BM was 22.7 months with fotemustine versus 7.2 months with DTIC (P = .059). Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P = .067). The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively). No significant difference was noted for quality of life between arms. Conclusion: ORR was higher in the fotemustine arm compared to the DTIC arm in first-line treatment of disseminated melanoma. A trend in favor of fotemustine in terms of overall survival and time to BM was evidenced.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,272
Self-citationChapman, P. B., Einhorn, L. H., Meyers, M. L., Saxman, S., Destro, A. N., Panageas, K. S., Begg, C. B., Agarwala, S. S., Schuchter, L. M., Ernstoff, M. S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2745 · Cited by 764
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone, L., Zeuli, M., Sega, F. M., & Cognetti, F. (2000) · PubMed · Cited by 350
Falkson, C. I., Ibrahim, J., Kirkwood, J. M., Coates, A. S., Atkins, M. B., & Blum, R. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1743 · Cited by 303
Fayers, P. M., Hopwood, P., Harvey, A., Girling, D. J., Machin, D., & Stephens, R. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00412-1 · Cited by 159
Margolin, K. A., Atkins, M. B., Thompson, J. F., Ernstoff, M. S., Weber, J. S., Flaherty, L. E., Clark, J. I., Weiss, G. R., Sosman, J. A., Smith, J. W., et al. (2002) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-002-0323-8 · Cited by 145
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma
Paul, M. J., Summers, Y. J., Calvert, A. H., et al. (2002) · Melanoma Research · doi:10.1097/00008390-200204000-00011 · Cited by 104
Middleton, M. R., Lorigan, P. C., Owen, J., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1056 · Cited by 100
Temozolomide Plus Thalidomide in Patients With Advanced Melanoma: Results of a Dose-Finding Trial
Hwu, W., Krown, S. E., Panageas, K. S., Menell, J. H., Chapman, P. B., Livingston, P. O., Williams, L. J., Quinn, C. J., & Houghton, A. N. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.034 · Cited by 65
Cited by
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationMcArthur, G. A., Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Dummer, R., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70012-9 · Cited by 977
Self-citationSenzer, N. N., Kaufman, H. L., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.3675 · Cited by 616
Bedikian, A. Y., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A. C., DeConti, R., Hersh, E. M., Hersey, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0483 · Cited by 600
Self-citationSystematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
Garbe, C., Eigentler, T. K., Keilholz, U., Hauschild, A., & Kirkwood, J. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0190 · Cited by 582
Self-citation
Metadata
- Authors
- Avril, M. F., Aamdal, S., Grob, J. J., Hauschild, A., Mohr, P., Bonerandi, J. J., Weichenthal, M., Neuber, K., Bieber, T., Gilde, K., Guillem Porta, V., Fra, J., Bonneterre, J., Saïag, P., Kamanabrou, D., Pehamberger, H., Sufliarsky, J., Gonzalez Larriba, J. L., Scherrer, A., & Menu, Y.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-03-15
- Volume
- 22
- Issue
- 6
- Pages
- 1118-1125
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2114847324
- Cited by
- 486
- References
- 11
- FWCI
- 8.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study. https://app.cochat.ai/papers/10.1200/jco.2004.04.165
- The paper
- Avril, M. F., Aamdal, S., Grob, J. J., Hauschild, A., Mohr, P., Bonerandi, J. J., Weichenthal, M., Neuber, K., Bieber, T., Gilde, K., Guillem Porta, V., Fra, J., Bonneterre, J., Saïag, P., Kamanabrou, D., Pehamberger, H., Sufliarsky, J., Gonzalez Larriba, J. L., Scherrer, A., & Menu, Y. (2004). Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.04.165
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.